
When investors evaluate a deep-tech or disruptive hardware companies for a Series B or C round, they often fall in love with the technology. Patents. Performance charts. Benchmark data that outpaces incumbents.
Months of diligence go into the physics, the IP landscape, and customer traction. But when it comes to operations, the conversation usually takes less than one percent of diligence time — a quick sync with the founder or VP Ops, often someone who’s never scaled production, launched products into the market, managed yield learning, or integrated quality systems at volume. That’s where most deep-tech investments quietly lose their edge.
In every breakthrough company I’ve seen, there’s a moment when the science works — but the system doesn’t. That moment separates the companies that scale from the ones that stall. The warning signs are subtle:
On the surface, the technology looks ready.
Underneath, it’s fragile.
Every deep-tech investor understands science risk.
Far fewer quantify execution risk — yet that’s what turns 10× potential into flat returns. Put simply, many companies can prove product-market fit, but lack the processes, systems, and leadership to translate early traction into scalable, repeatable delivery. Series B and C investors should be asking:
If those answers aren’t clear before the round closes, you’re not investing — you’re hoping.
For deep-tech companies, an Operational Assessment isn’t about red tape.
It’s about validating that the company can turn capital into capacity — not just patents into press releases. It uncovers what technical and financial diligence miss:
Before you write the next Series B or C check, pause.
Make operational readiness a non-negotiable part of deep-tech diligence — and call me before you wire the money.